2026 Q2 Portfolio Activity
In 2026 Q2, Avidity Partners Management LP maintained a portfolio of 56 distinct positions. The most significant new addition was CG ONCOLOGY INC, now representing 15.92% of the total fund value. They heavily accumulated shares in AKTIS ONCOLOGY INC, increasing the position by 24.9%. The fund also reduced its exposure to AKTIS ONCOLOGY INC by 44.5%.
Position History
hover any row below to update
Loading…
Total Positions
56
Quarter
2026 Q2
Top Holding
DNTH (32.8%)
Top 10 Concentration
81.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 56
Avidity Partners Management LP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 32.85% | 41.81% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
2,104,184 | $205,115,856 |
$116.98
nan%
|
2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 15.92% | — |
#2
Prev: #—
|
9.0 |
—
|
1,398,948 | — |
NEW
|
1,398,948 | $99,395,255 |
$31.78
+135.0%
|
2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 11.59% | 11.77% |
#3
1
Prev: #2
|
6.0 |
—
|
no change | no change |
P
S
|
760,424 | $72,369,552 |
$32.00
+189.1%
|
2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
JBIO
JADE BIOSCIENCE...
|
Healthcare | 6.05% | 7.73% |
#4
1
Prev: #3
|
5.4 |
—
|
300,000 | 21.4% |
P
S
|
1,700,708 | $37,789,732 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 4.47% | 3.73% |
#5
Prev: #5
|
4.8 |
—
|
150,000 | 37.5% |
P
S
|
550,000 | $27,912,500 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 3.44% | 5.34% |
#6
2
Prev: #4
|
1.9 |
—
|
250,000 | 4.1% |
P
S
|
6,299,999 | $21,482,997 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
AKTIS ONCOLOGY ...
|
|
Unknown | 2.50% | 1.99% |
#7
2
Prev: #9
|
1.5 |
—
|
15,634 | 3.3% |
P
S
|
484,200 | $15,605,766 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
PVLA
PALVELLA THERAP...
|
Healthcare | 1.71% | 2.03% |
#8
Prev: #8
|
1.7 |
—
|
no change | no change |
P
S
|
70,000 | $10,697,400 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
MOBIA MED INC
|
|
Unknown | 1.71% | — |
#9
Prev: #—
|
4.2 |
—
|
798,282 | — |
NEW
|
798,282 | $10,696,979 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
RGEN
REPLIGEN CORP
|
Healthcare | 1.70% | 2.08% |
#10
3
Prev: #7
|
1.7 |
—
|
no change | no change |
P
S
|
77,800 | $10,615,032 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
IMMUNIC INC
|
|
Unknown | 1.65% | — |
#11
Prev: #—
|
4.2 |
—
|
669,941 | — |
NEW
|
669,941 | $10,296,993 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
SENS
SENSEONICS HLDG...
|
Healthcare | 1.46% | — |
#12
Prev: #—
|
4.1 |
—
|
1,600,000 | — |
NEW
|
1,600,000 | $9,088,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KPTI
KARYOPHARM THER...
|
Healthcare | 1.45% | 0.87% |
#13
4
Prev: #17
|
3.6 |
—
|
460,746 | 99.4% |
P
S
|
924,487 | $9,032,238 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TEVA
TEVA PHARMACEUT...
|
Healthcare | 1.09% | 1.59% |
#14
3
Prev: #11
|
1.4 |
—
|
no change | no change |
P
S
|
200,000 | $6,776,000 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DXCM
DEXCOM INC
|
Healthcare | 1.08% | 1.35% |
#15
1
Prev: #14
|
1.4 |
—
|
no change | no change |
P
S
|
100,000 | $6,735,000 | 2022 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TEM
TEMPUS AI INC
|
Healthcare | 0.97% | 0.82% |
#16
2
Prev: #18
|
3.4 |
—
|
40,000 | 61.5% |
P
S
|
105,000 | $6,082,650 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MDT
MEDTRONIC PLC
|
Healthcare | 0.88% | 1.83% |
#17
7
Prev: #10
|
0.4 |
—
|
-30,000 | -30.0% |
P
S
|
70,000 | $5,476,100 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VIR
VIR BIOTECHNOLO...
|
Healthcare | 0.85% | 1.43% |
#18
5
Prev: #13
|
0.8 |
—
|
-100,000 | -16.1% |
P
S
|
519,300 | $5,291,667 | 2020 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.84% | 0.45% |
#19
5
Prev: #24
|
3.3 |
—
|
50,000 | 104.2% |
P
S
|
98,000 | $5,259,660 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
EHC
ENCOMPASS HEALT...
|
Healthcare | 0.68% | 0.95% |
#20
4
Prev: #16
|
1.3 |
—
|
no change | no change |
P
S
|
42,000 | $4,245,360 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TENX
TENAX THERAPEUT...
|
Healthcare | 0.62% | 0.79% |
#21
2
Prev: #19
|
1.2 |
—
|
no change | no change |
P
S
|
265,934 | $3,869,340 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NVCT
NUVECTIS PHARMA...
|
Healthcare | 0.59% | — |
#22
Prev: #—
|
3.7 |
—
|
200,000 | — |
NEW
|
200,000 | $3,678,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PODD
INSULET CORP
|
Healthcare | 0.59% | 0.39% |
#23
6
Prev: #29
|
3.2 |
—
|
14,000 | 140.0% |
P
S
|
24,000 | $3,654,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BSX
BOSTON SCIENTIF...
|
Healthcare | 0.55% | 0.78% |
#24
4
Prev: #20
|
2.7 |
—
|
20,000 | 33.3% |
P
S
|
80,000 | $3,414,400 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
SATELLOS BIOSCI...
|
|
Unknown | 0.48% | 0.70% |
#25
4
Prev: #21
|
1.2 |
—
|
no change | no change |
P
S
|
387,769 | $3,014,904 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
N/A
ALAMAR BIOSCIEN...
|
|
Unknown | 0.48% | — |
#26
Prev: #—
|
3.7 |
—
|
110,000 | — |
NEW
|
110,000 | $2,979,900 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 0.44% | 2.67% |
#27
21
Prev: #6
|
1.2 |
—
|
no change | no change |
P
S
|
4,998,267 | $2,768,540 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GILD
GILEAD SCIENCES...
|
Healthcare | 0.40% | 0.59% |
#28
5
Prev: #23
|
1.2 |
—
|
no change | no change |
P
S
|
20,000 | $2,526,800 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CRL
CHARLES RIV LAB...
|
Healthcare | 0.36% | 0.38% |
#29
1
Prev: #30
|
1.1 |
—
|
no change | no change |
P
S
|
10,000 | $2,267,900 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PHAT
PHATHOM PHARMAC...
|
Healthcare | 0.35% | 0.63% |
#30
8
Prev: #22
|
0.6 |
—
|
-49,390 | -19.8% |
P
S
|
200,000 | $2,170,000 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
AVALYN PHARMACE...
|
|
Unknown | 0.32% | — |
#31
Prev: #—
|
3.6 |
—
|
60,000 | — |
NEW
|
60,000 | $1,975,200 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
N/A
KAILERA THERAPE...
|
|
Unknown | 0.28% | — |
#32
Prev: #—
|
3.6 |
—
|
80,000 | — |
NEW
|
80,000 | $1,762,400 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
GMAB
GENMAB A/S
|
Healthcare | 0.22% | 0.30% |
#33
Prev: #33
|
1.1 |
—
|
no change | no change |
P
S
|
50,000 | $1,373,500 | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NTLA
INTELLIA THERAP...
|
Healthcare | 0.20% | 0.23% |
#34
1
Prev: #35
|
1.1 |
—
|
no change | no change |
P
S
|
75,000 | $1,269,000 | 2020 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CRVS
CORVUS PHARMACE...
|
Healthcare | 0.19% | 0.40% |
#35
7
Prev: #28
|
0.1 |
—
|
-35,000 | -30.4% |
P
S
|
80,000 | $1,195,200 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ODD
ODDITY TECH LTD
|
Consumer Defensive | 0.17% | 0.23% |
#36
Prev: #36
|
1.1 |
—
|
no change | no change |
P
S
|
70,000 | $1,059,100 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
SCYNEXIS INC
|
|
Unknown | 0.17% | — |
#37
Prev: #—
|
3.6 |
—
|
260,206 | — |
NEW
|
260,206 | $1,059,038 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
EVMN
EVOMMUNE INC
|
Healthcare | 0.16% | — |
#38
Prev: #—
|
3.6 |
—
|
75,000 | — |
NEW
|
75,000 | $996,750 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ABT
ABBOTT LABORATO...
|
Healthcare | 0.15% | 0.21% |
#39
1
Prev: #38
|
1.1 |
—
|
no change | no change |
P
S
|
10,000 | $907,400 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 0.12% | 0.16% |
#40
Prev: #40
|
1.0 |
—
|
no change | no change |
P
S
|
10,000 | $744,800 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PTON
PELOTON INTERAC...
|
Consumer Cyclical | 0.09% | 0.25% |
#41
7
Prev: #34
|
0.0 |
—
|
-100,000 | -50.0% |
P
S
|
100,000 | $591,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LEGN
LEGEND BIOTECH ...
|
Healthcare | 0.07% | 0.08% |
#42
1
Prev: #43
|
1.0 |
—
|
no change | no change |
P
S
|
15,000 | $433,200 | 2020 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 0.05% | 0.08% |
#43
1
Prev: #42
|
1.0 |
—
|
no change | no change |
P
S
|
43,853 | $334,160 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SVRA
SAVARA INC
|
Healthcare | 0.05% | 0.06% |
#44
1
Prev: #45
|
1.0 |
—
|
no change | no change |
P
S
|
50,000 | $308,000 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 0.02% | 0.02% |
#45
1
Prev: #46
|
1.0 |
—
|
no change | no change |
P
S
|
6,660 | $124,209 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ACAD
ACADIA PHARMACE...
|
Healthcare | 0.00% | 0.07% |
Sold All 😨
(Was: #44) |
0.0 |
—
|
-12,967 | -100.0% |
CLOSED
|
— | $— | 2019 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ABUS
ARBUTUS BIOPHAR...
|
Healthcare | 0.00% | 0.12% |
Sold All 😨
(Was: #41) |
0.0 |
—
|
-125,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 0.00% | 0.19% |
Sold All 😨
(Was: #39) |
0.0 |
—
|
-50,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AVR
ANTERIS TECHNOL...
|
Healthcare | 0.00% | 0.21% |
Sold All 😨
(Was: #37) |
0.0 |
—
|
-150,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
HIMS
HIMS & HERS HEA...
|
Healthcare | 0.00% | 0.31% |
Sold All 😨
(Was: #32) |
0.0 |
—
|
-50,000 | -100.0% |
CLOSED
|
— | $— | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-50 of 56 holdings